Singh Ranee, Reed Anthony N, Chu Peifei, Scully Conor C G, Yau Mei-Kwan, Suen Jacky Y, Durek Thomas, Reid Robert C, Fairlie David P
Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Bioorg Med Chem Lett. 2015 Dec 1;25(23):5604-8. doi: 10.1016/j.bmcl.2015.10.038. Epub 2015 Oct 23.
Potent ligands for the human complement C3a receptor (C3aR) were developed from the almost inactive tripeptide Leu-Ala-Arg corresponding to the three C-terminal residues of the endogenous peptide agonist C3a. The analogous Leu-Ser-Arg was modified by condensing the serine side chain with the leucine carbonyl with elimination of water to form leucine-oxazole-arginine. Subsequent elaboration with a variety of N-terminal amide capping groups produced agonists as potent as human C3a itself in stimulating Ca(2+) release from human macrophages. Structure-activity relationships are discussed.
人类补体C3a受体(C3aR)的强效配体是由与内源性肽激动剂C3a的三个C末端残基对应的几乎无活性的三肽Leu-Ala-Arg开发而来。类似的Leu-Ser-Arg通过将丝氨酸侧链与亮氨酸羰基缩合并消除水以形成亮氨酸-恶唑-精氨酸进行修饰。随后用各种N末端酰胺封端基团进行精细合成,产生了在刺激人巨噬细胞释放Ca(2+)方面与人C3a本身一样有效的激动剂。讨论了构效关系。